(Q26852293)

English

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials

scientific article published in July 2014

In more languages

Statements

scholarly article

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials (English)

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D. Sanford

1

1 reference

A. Naidu

2

1 reference

N. Alizadeh

3

1 reference

A. Lazo-Langner

4

1 reference

language of work or name

1 reference

publication date

July 2014

1 reference

Journal of Thrombosis and Haemostasis

1 reference

12

1 reference

7

1 reference

1076-85

1 reference

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Alternatively spliced tissue factor induces angiogenesis through integrin ligation.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Inhibition of tissue factor signaling suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Heparin and chemotherapy in the management of inoperable lung carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Allocation concealment in randomised trials: defending against deciphering

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1111/JTH.12595

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_ihkjaveaorbullgxysjcd5q3ka

1 reference

https://api.fatcat.wiki/v0/release/ihkjaveaorbullgxysjcd5q3ka

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26852293&oldid=1840064131"